Annual EBITDA
-$38.24 M
-$530.00 K-1.41%
December 31, 2023
Summary
- As of February 7, 2025, GALT annual EBITDA is -$38.24 million, with the most recent change of -$530.00 thousand (-1.41%) on December 31, 2023.
- During the last 3 years, GALT annual EBITDA has fallen by -$14.90 million (-63.83%).
- GALT annual EBITDA is now -1662.34% below its all-time high of -$2.17 million, reached on December 31, 2001.
Performance
GALT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$9.72 M
+$1.38 M+12.40%
September 30, 2024
Summary
- As of February 7, 2025, GALT quarterly EBITDA is -$9.72 million, with the most recent change of +$1.38 million (+12.40%) on September 30, 2024.
- Over the past year, GALT quarterly EBITDA has dropped by -$132.00 thousand (-1.38%).
- GALT quarterly EBITDA is now -1570.45% below its all-time high of -$581.70 thousand, reached on June 30, 2001.
Performance
GALT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$40.38 M
-$132.00 K-0.33%
September 30, 2024
Summary
- As of February 7, 2025, GALT TTM EBITDA is -$40.38 million, with the most recent change of -$132.00 thousand (-0.33%) on September 30, 2024.
- Over the past year, GALT TTM EBITDA has dropped by -$977.00 thousand (-2.48%).
- GALT TTM EBITDA is now -6841.55% below its all-time high of -$581.70 thousand, reached on June 30, 2001.
Performance
GALT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
GALT EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -1.4% | -1.4% | -2.5% |
| 3 y3 years | -63.8% | -15.7% | -30.8% |
| 5 y5 years | -181.9% | -90.3% | -206.6% |
GALT EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -27.5% | at low | -40.0% | +12.4% | -34.6% | at low |
| 5 y | 5-year | -190.3% | at low | -175.7% | +12.4% | -206.6% | at low |
| alltime | all time | -1662.3% | at low | -1570.5% | +12.4% | -6841.6% | at low |
Galectin Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$9.72 M(-12.4%) | -$40.38 M(+0.3%) |
| Jun 2024 | - | -$11.09 M(+6.4%) | -$40.25 M(+7.0%) |
| Mar 2024 | - | -$10.43 M(+14.1%) | -$37.62 M(-1.6%) |
| Dec 2023 | -$38.24 M(+1.4%) | -$9.14 M(-4.6%) | -$38.23 M(-3.0%) |
| Sep 2023 | - | -$9.59 M(+13.2%) | -$39.40 M(+3.3%) |
| Jun 2023 | - | -$8.46 M(-23.3%) | -$38.14 M(-2.3%) |
| Mar 2023 | - | -$11.04 M(+6.9%) | -$39.05 M(+3.6%) |
| Dec 2022 | -$37.71 M(+25.7%) | -$10.32 M(+24.0%) | -$37.71 M(+9.8%) |
| Sep 2022 | - | -$8.32 M(-11.3%) | -$34.33 M(-0.2%) |
| Jun 2022 | - | -$9.38 M(-3.3%) | -$34.41 M(+3.1%) |
| Mar 2022 | - | -$9.70 M(+39.7%) | -$33.39 M(+11.3%) |
| Dec 2021 | -$30.00 M(+28.5%) | -$6.94 M(-17.4%) | -$30.00 M(-2.9%) |
| Sep 2021 | - | -$8.40 M(+0.5%) | -$30.88 M(+8.8%) |
| Jun 2021 | - | -$8.35 M(+32.5%) | -$28.39 M(+8.7%) |
| Mar 2021 | - | -$6.31 M(-19.4%) | -$26.12 M(+11.9%) |
| Dec 2020 | -$23.34 M(+77.2%) | -$7.82 M(+32.3%) | -$23.34 M(+13.2%) |
| Sep 2020 | - | -$5.91 M(-2.9%) | -$20.63 M(+18.1%) |
| Jun 2020 | - | -$6.08 M(+72.6%) | -$17.47 M(+21.7%) |
| Mar 2020 | - | -$3.52 M(-31.0%) | -$14.35 M(+9.0%) |
| Dec 2019 | -$13.17 M(-2.9%) | -$5.11 M(+85.4%) | -$13.17 M(+19.4%) |
| Sep 2019 | - | -$2.75 M(-7.2%) | -$11.04 M(+0.8%) |
| Jun 2019 | - | -$2.97 M(+26.7%) | -$10.95 M(-6.7%) |
| Mar 2019 | - | -$2.34 M(-21.1%) | -$11.73 M(-13.5%) |
| Dec 2018 | -$13.56 M(-16.4%) | -$2.97 M(+11.4%) | -$13.56 M(+4.8%) |
| Sep 2018 | - | -$2.67 M(-29.0%) | -$12.94 M(-11.9%) |
| Jun 2018 | - | -$3.75 M(-10.0%) | -$14.69 M(-4.9%) |
| Mar 2018 | - | -$4.17 M(+77.7%) | -$15.45 M(-4.7%) |
| Dec 2017 | -$16.22 M(-24.3%) | -$2.35 M(-46.8%) | -$16.21 M(-12.0%) |
| Sep 2017 | - | -$4.41 M(-2.2%) | -$18.42 M(-0.7%) |
| Jun 2017 | - | -$4.51 M(-8.5%) | -$18.54 M(-5.2%) |
| Mar 2017 | - | -$4.94 M(+8.4%) | -$19.55 M(-8.8%) |
| Dec 2016 | -$21.43 M(+6.8%) | -$4.55 M(+0.4%) | -$21.43 M(-0.6%) |
| Sep 2016 | - | -$4.54 M(-18.0%) | -$21.56 M(-5.9%) |
| Jun 2016 | - | -$5.53 M(-18.8%) | -$22.92 M(+4.0%) |
| Mar 2016 | - | -$6.81 M(+45.5%) | -$22.05 M(+9.8%) |
| Dec 2015 | -$20.07 M(+30.2%) | -$4.68 M(-20.6%) | -$20.07 M(+5.0%) |
| Sep 2015 | - | -$5.90 M(+26.7%) | -$19.12 M(+14.5%) |
| Jun 2015 | - | -$4.66 M(-3.8%) | -$16.70 M(+8.3%) |
| Mar 2015 | - | -$4.84 M(+29.6%) | -$15.42 M(-0.0%) |
| Dec 2014 | -$15.42 M(+27.5%) | -$3.73 M(+7.4%) | -$15.42 M(+6.4%) |
| Sep 2014 | - | -$3.47 M(+3.0%) | -$14.49 M(-0.5%) |
| Jun 2014 | - | -$3.37 M(-30.4%) | -$14.56 M(+6.0%) |
| Mar 2014 | - | -$4.84 M(+72.9%) | -$13.73 M(+13.6%) |
| Dec 2013 | -$12.09 M(+22.3%) | -$2.80 M(-20.9%) | -$12.09 M(+1.7%) |
| Sep 2013 | - | -$3.54 M(+39.2%) | -$11.88 M(+7.7%) |
| Jun 2013 | - | -$2.54 M(-20.5%) | -$11.03 M(-1.0%) |
| Mar 2013 | - | -$3.20 M(+23.3%) | -$11.14 M(+12.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2012 | -$9.89 M(-9.3%) | -$2.60 M(-3.4%) | -$9.89 M(-11.5%) |
| Sep 2012 | - | -$2.69 M(+1.1%) | -$11.17 M(+6.2%) |
| Jun 2012 | - | -$2.66 M(+36.4%) | -$10.51 M(-3.0%) |
| Mar 2012 | - | -$1.95 M(-49.7%) | -$10.84 M(-0.6%) |
| Dec 2011 | -$10.91 M(+123.9%) | -$3.88 M(+90.8%) | -$10.91 M(+31.1%) |
| Sep 2011 | - | -$2.03 M(-32.0%) | -$8.32 M(+11.0%) |
| Jun 2011 | - | -$2.99 M(+48.6%) | -$7.50 M(+28.0%) |
| Mar 2011 | - | -$2.01 M(+56.1%) | -$5.85 M(+20.2%) |
| Dec 2010 | -$4.87 M(-19.6%) | -$1.29 M(+6.5%) | -$4.87 M(+3.8%) |
| Sep 2010 | - | -$1.21 M(-10.2%) | -$4.69 M(-0.7%) |
| Jun 2010 | - | -$1.35 M(+30.9%) | -$4.72 M(-11.9%) |
| Mar 2010 | - | -$1.03 M(-7.4%) | -$5.36 M(-11.5%) |
| Dec 2009 | -$6.06 M(+14.8%) | -$1.11 M(-10.6%) | -$6.06 M(+0.3%) |
| Sep 2009 | - | -$1.24 M(-37.4%) | -$6.04 M(+5.5%) |
| Jun 2009 | - | -$1.98 M(+15.0%) | -$5.72 M(+2.1%) |
| Mar 2009 | - | -$1.72 M(+57.9%) | -$5.60 M(+6.2%) |
| Dec 2008 | -$5.28 M(-17.4%) | -$1.09 M(+17.7%) | -$5.28 M(-5.1%) |
| Sep 2008 | - | -$927.00 K(-50.2%) | -$5.56 M(-7.1%) |
| Jun 2008 | - | -$1.86 M(+33.3%) | -$5.99 M(+1.8%) |
| Mar 2008 | - | -$1.40 M(+1.5%) | -$5.88 M(-8.0%) |
| Dec 2007 | -$6.39 M(-8.5%) | -$1.38 M(+1.8%) | -$6.39 M(+1.6%) |
| Sep 2007 | - | -$1.35 M(-23.0%) | -$6.29 M(-8.2%) |
| Jun 2007 | - | -$1.76 M(-7.9%) | -$6.86 M(-4.6%) |
| Mar 2007 | - | -$1.91 M(+49.2%) | -$7.18 M(+2.9%) |
| Dec 2006 | -$6.98 M(+6.2%) | -$1.28 M(-33.2%) | -$6.98 M(-6.2%) |
| Sep 2006 | - | -$1.91 M(-8.2%) | -$7.44 M(+3.2%) |
| Jun 2006 | - | -$2.08 M(+22.2%) | -$7.21 M(+5.4%) |
| Mar 2006 | - | -$1.71 M(-2.0%) | -$6.84 M(+4.1%) |
| Dec 2005 | -$6.57 M(-9.0%) | -$1.74 M(+3.3%) | -$6.57 M(-6.2%) |
| Sep 2005 | - | -$1.69 M(-1.6%) | -$7.01 M(-1.3%) |
| Jun 2005 | - | -$1.71 M(+19.1%) | -$7.11 M(+4.0%) |
| Mar 2005 | - | -$1.44 M(-34.0%) | -$6.83 M(-4.6%) |
| Dec 2004 | -$7.22 M(+49.0%) | -$2.18 M(+22.3%) | -$7.16 M(+9.2%) |
| Sep 2004 | - | -$1.78 M(+23.9%) | -$6.56 M(+6.5%) |
| Jun 2004 | - | -$1.44 M(-18.7%) | -$6.16 M(+8.4%) |
| Mar 2004 | - | -$1.77 M(+12.4%) | -$5.68 M(+17.2%) |
| Dec 2003 | -$4.85 M(+57.6%) | -$1.57 M(+14.2%) | -$4.85 M(+15.9%) |
| Sep 2003 | - | -$1.38 M(+43.3%) | -$4.18 M(+21.9%) |
| Jun 2003 | - | -$961.80 K(+2.7%) | -$3.43 M(+3.6%) |
| Mar 2003 | - | -$936.20 K(+3.1%) | -$3.31 M(+7.9%) |
| Dec 2002 | -$3.08 M(+41.8%) | -$908.00 K(+45.2%) | -$3.07 M(+6.0%) |
| Sep 2002 | - | -$625.50 K(-25.7%) | -$2.89 M(+0.5%) |
| Jun 2002 | - | -$841.50 K(+21.5%) | -$2.88 M(+9.9%) |
| Mar 2002 | - | -$692.60 K(-5.5%) | -$2.62 M(+35.9%) |
| Dec 2001 | -$2.17 M | -$733.10 K(+19.8%) | -$1.93 M(+61.4%) |
| Sep 2001 | - | -$611.90 K(+5.2%) | -$1.19 M(+105.2%) |
| Jun 2001 | - | -$581.70 K | -$581.70 K |
FAQ
- What is Galectin Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Galectin Therapeutics?
- What is Galectin Therapeutics annual EBITDA year-on-year change?
- What is Galectin Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Galectin Therapeutics?
- What is Galectin Therapeutics quarterly EBITDA year-on-year change?
- What is Galectin Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Galectin Therapeutics?
- What is Galectin Therapeutics TTM EBITDA year-on-year change?
What is Galectin Therapeutics annual EBITDA?
The current annual EBITDA of GALT is -$38.24 M
What is the all time high annual EBITDA for Galectin Therapeutics?
Galectin Therapeutics all-time high annual EBITDA is -$2.17 M
What is Galectin Therapeutics annual EBITDA year-on-year change?
Over the past year, GALT annual EBITDA has changed by -$530.00 K (-1.41%)
What is Galectin Therapeutics quarterly EBITDA?
The current quarterly EBITDA of GALT is -$9.72 M
What is the all time high quarterly EBITDA for Galectin Therapeutics?
Galectin Therapeutics all-time high quarterly EBITDA is -$581.70 K
What is Galectin Therapeutics quarterly EBITDA year-on-year change?
Over the past year, GALT quarterly EBITDA has changed by -$132.00 K (-1.38%)
What is Galectin Therapeutics TTM EBITDA?
The current TTM EBITDA of GALT is -$40.38 M
What is the all time high TTM EBITDA for Galectin Therapeutics?
Galectin Therapeutics all-time high TTM EBITDA is -$581.70 K
What is Galectin Therapeutics TTM EBITDA year-on-year change?
Over the past year, GALT TTM EBITDA has changed by -$977.00 K (-2.48%)